366 related articles for article (PubMed ID: 15912274)
1. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain.
Elsinga PH; Hendrikse NH; Bart J; van Waarde A; Vaalburg W
Mol Imaging Biol; 2005; 7(1):37-44. PubMed ID: 15912274
[TBL] [Abstract][Full Text] [Related]
2. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS.
Elsinga PH; Hendrikse NH; Bart J; Vaalburg W; van Waarde A
Curr Pharm Des; 2004; 10(13):1493-503. PubMed ID: 15134571
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier.
Doze P; Van Waarde A; Elsinga PH; Hendrikse NH; Vaalburg W
Synapse; 2000 Apr; 36(1):66-74. PubMed ID: 10700027
[TBL] [Abstract][Full Text] [Related]
4. Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar.
la Fougère C; Böning G; Bartmann H; Wängler B; Nowak S; Just T; Wagner E; Winter P; Rominger A; Förster S; Gildehaus FJ; Rosa-Neto P; Minuzzi L; Bartenstein P; Potschka H; Cumming P
Neuroimage; 2010 Jan; 49(2):1406-15. PubMed ID: 19796699
[TBL] [Abstract][Full Text] [Related]
5. New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics.
Bart J; Dijkers EC; Wegman TD; de Vries EG; van der Graaf WT; Groen HJ; Vaalburg W; Willemsen AT; Hendrikse NH
Br J Pharmacol; 2005 Aug; 145(8):1045-51. PubMed ID: 15951832
[TBL] [Abstract][Full Text] [Related]
6. Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY.
Liow JS; Lu S; McCarron JA; Hong J; Musachio JL; Pike VW; Innis RB; Zoghbi SS
Synapse; 2007 Feb; 61(2):96-105. PubMed ID: 17117422
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies.
Laćan G; Plenevaux A; Rubins DJ; Way BM; Defraiteur C; Lemaire C; Aerts J; Luxen A; Cherry SR; Melega WP
Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2256-66. PubMed ID: 18604533
[TBL] [Abstract][Full Text] [Related]
8. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N
Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486
[TBL] [Abstract][Full Text] [Related]
9. Importance of P-gp PET Imaging in Pharmacology.
Toyohara J
Curr Pharm Des; 2016; 22(38):5830-5836. PubMed ID: 27494065
[TBL] [Abstract][Full Text] [Related]
10. Discrepancies in the P-glycoprotein-mediated transport of (18)F-MPPF: a pharmacokinetic study in mice and non-human primates.
Tournier N; Cisternino S; Peyronneau MA; Goutal S; Dolle F; Scherrmann JM; Bottlaender M; Saba W; Valette H
Pharm Res; 2012 Sep; 29(9):2468-76. PubMed ID: 22644589
[TBL] [Abstract][Full Text] [Related]
11. Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition.
Ke AB; Eyal S; Chung FS; Link JM; Mankoff DA; Muzi M; Unadkat JD
J Nucl Med; 2013 Mar; 54(3):437-46. PubMed ID: 23359659
[TBL] [Abstract][Full Text] [Related]
12. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of P-glycoprotein (abcb1a/b) modulation of [(18)F]fallypride in MicroPET imaging studies.
Piel M; Schmitt U; Bausbacher N; Buchholz HG; Gründer G; Hiemke C; Rösch F
Neuropharmacology; 2014 Sep; 84():152-8. PubMed ID: 23994301
[TBL] [Abstract][Full Text] [Related]
14. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET.
Bart J; Willemsen AT; Groen HJ; van der Graaf WT; Wegman TD; Vaalburg W; de Vries EG; Hendrikse NH
Neuroimage; 2003 Nov; 20(3):1775-82. PubMed ID: 14642487
[TBL] [Abstract][Full Text] [Related]
15.
García-Varela L; Rodríguez-Pérez M; Custodia A; Moraga-Amaro R; Colabufo NA; Aguiar P; Sobrino T; Dierckx RAJO; van Waarde A; Elsinga PH; Luurtsema G
Mol Pharm; 2021 Aug; 18(8):3073-3085. PubMed ID: 34228458
[TBL] [Abstract][Full Text] [Related]
16. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate.
Eyal S; Chung FS; Muzi M; Link JM; Mankoff DA; Kaddoumi A; O'Sullivan F; Hebert MF; Unadkat JD
J Nucl Med; 2009 May; 50(5):798-806. PubMed ID: 19403878
[TBL] [Abstract][Full Text] [Related]
18. Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study.
Liu L; Collier AC; Link JM; Domino KB; Mankoff DA; Eary JF; Spiekerman CF; Hsiao P; Deo AK; Unadkat JD
Drug Metab Dispos; 2015 Nov; 43(11):1795-804. PubMed ID: 26354948
[TBL] [Abstract][Full Text] [Related]
19. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically.
Ishiwata K; Kawamura K; Yanai K; Hendrikse NH
J Nucl Med; 2007 Jan; 48(1):81-7. PubMed ID: 17204702
[TBL] [Abstract][Full Text] [Related]
20. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB
J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
